Does Mounjaro wear off as the week goes on?

Why blood levels fall before your next injection is due

The approved clinical data and the Mounjaro Summary of Product Characteristics confirm that tirzepatide's terminal half-life sits at around five days. After a subcutaneous injection the medicine is absorbed over roughly one to two days, reaches peak plasma concentration, then declines in a predictable curve. By the time you are approaching injection day again, your circulating tirzepatide level is noticeably lower than it was on day two or three. This is not a defect in the medicine; it is simply how a weekly subcutaneous GLP-1 and GIP receptor agonist works in the body.

The NHS tirzepatide medicines page explains that tirzepatide slows how quickly the stomach empties and acts on receptors involved in appetite regulation. When the concentration at those receptors is higher, appetite suppression is more pronounced. When it falls, the effect softens. Most people who notice this describe it as a gradual shift rather than a cliff edge, and many find it steadies as they move up the dose schedule — because higher maintenance doses mean a higher baseline concentration at every point in the cycle.

One thing worth noting: a question our prescribers hear most weeks is whether the late-week feelings mean the treatment is wearing off for good. The evidence from the SURMOUNT-1 trial, published in the New England Journal of Medicine, showed continued average weight reduction across 72 weeks at all active doses, the weekly rhythm of blood levels did not prevent meaningful, sustained results. The body's response stabilises over time even as the within-week fluctuation persists. For a fuller look at when and why these effects shift during the cycle, we have covered the pharmacokinetics in more detail separately.

How the weekly ebb actually feels, and what is within the expected range

People typically notice one or more of the following toward the end of their injection cycle: hunger returning more readily at mealtimes, smaller portions feeling less satisfying, a mild return of food cravings, or simply a sense that the medicine's presence is fading. These experiences sit within the normal range for a medicine with a five-day half-life. They are not evidence that tirzepatide has stopped being effective, and they do not mean the next injection will be less useful.

What falls outside the expected range is a sharp, sudden loss of appetite suppression early in the cycle, say, on day two or three. That pattern is more likely linked to something else: a delayed or missed dose, a storage issue affecting the pen, or an unrelated change in eating habits. For practical information about how the effect tends to shift during the week, that page goes into the day-by-day picture in more detail.

It is also worth separating two things: changes in appetite suppression and changes in tolerability. Some people find nausea, which can be more noticeable in the first days after injection, improves toward the end of the week. The late-week period may actually feel more comfortable even as appetite control eases. Both are expected features of the drug's concentration curve. If you are wondering whether Mounjaro wears off by the end of the week, that is a question we look at in detail alongside the concentration curve. If you are also interested in how tirzepatide affects body composition alongside weight, that is a separate but related part of the treatment picture worth understanding.

When to raise late-week symptoms with your prescriber

A gradual late-week softening of appetite suppression is expected and does not usually require any clinical intervention. What is worth raising with a prescriber is a pattern that interferes significantly with the week: for instance, pronounced hunger from day four onwards that makes dietary changes difficult to sustain, or a clear deterioration compared with earlier in treatment.

In those cases, a prescriber may consider whether the current dose is right for you, whether your titration timing is optimal, or whether other factors (sleep, stress, highly palatable foods) are amplifying the effect. Dose decisions are always clinical; no online resource, including this one, can tell you what adjustment is right for your situation. The prescribing guidance published by NICE in its tirzepatide appraisal (TA1026) emphasises continued clinical review throughout treatment, precisely because individual responses vary.

At the same time, the late-week dip does not, by itself, mean you need a higher dose sooner. Titration follows a schedule set by your prescriber for good reason: moving up too quickly increases the risk of gastrointestinal side effects. If you are weighing up how your current experience compares with what others report, a look at the broader late-week experience of tirzepatide may add some useful context. And if you are new to the treatment, the Mounjaro overview page covers the full clinical picture from the start.

What this means in practice, and when private assessment is an option

Understanding the pharmacokinetics of your weekly injection can make the late-week experience feel less unsettling and easier to manage. It also helps set realistic expectations: tirzepatide's results accumulate across months, not within individual weekly cycles. Short-term fluctuation in how hungry you feel on day six is entirely compatible with sustained, clinically meaningful weight loss over time.

If you have been trying to access treatment through the NHS, the current criteria are specific and phased, many people find private assessment a practical alternative. On the weight-loss treatments page, you can start a free consultation with a GPhC-registered prescriber who will review your full health picture, the same day where possible. Our clinical team reviews every case personally; nothing goes through an algorithm. For those still weighing up the private route, the treatment overview sets out what is available and what the process involves. If you have specific questions before starting, the FAQs page covers the most common ones in detail.